IQVIA (NYSE:IQV) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a report released on Saturday morning.

IQV has been the topic of a number of other research reports. Robert W. Baird dropped their target price on shares of IQVIA from $254.00 to $245.00 and set a neutral rating on the stock in a report on Friday, May 3rd. Truist Financial dropped their target price on shares of IQVIA from $297.00 to $292.00 and set a buy rating on the stock in a report on Friday, May 3rd. The Goldman Sachs Group assumed coverage on shares of IQVIA in a report on Thursday, June 6th. They set a buy rating and a $270.00 target price on the stock. Barclays dropped their price target on shares of IQVIA from $275.00 to $255.00 and set an overweight rating on the stock in a research note on Friday. Finally, Evercore ISI dropped their price target on shares of IQVIA from $275.00 to $250.00 and set an outperform rating on the stock in a research note on Friday, May 3rd. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of Moderate Buy and an average target price of $257.73.

IQVIA Stock Down 1.4 %

Shares of IQVIA stock opened at $208.49 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The company’s fifty day simple moving average is $223.93 and its two-hundred day simple moving average is $230.18. The company has a market cap of $37.99 billion, a P/E ratio of 28.48, a PEG ratio of 1.93 and a beta of 1.49. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. Research analysts anticipate that IQVIA will post 10.11 EPS for the current year.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently made changes to their positions in IQV. Norges Bank purchased a new stake in shares of IQVIA during the 4th quarter valued at about $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of IQVIA by 339.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after purchasing an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC increased its position in shares of IQVIA by 96.9% during the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Capital Research Global Investors increased its position in shares of IQVIA by 42.2% during the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after purchasing an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP purchased a new stake in IQVIA in the 4th quarter worth approximately $70,108,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.